All News
Updates on Reproductive Health in Women with SLE
Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.
What’s new to treat PsA? Let’s discuss anti-IL-17A, Izokibep #ACR22 @RheumNow
Abstract #0199
💪 Izokibep 40 v. 80 mg q2 weeks SQ v. placebo
💪 135 patients, 28 sites
💪 At 12 weeks, all patient reported outcomes and PsAID subdomains significantly improved (dose dependent)
Catherine Sims, MD DrCassySims ( View Tweet)
Another study showing treatment withdrawal does not work.
Golimumab withdrawal in nr-axSpA is inferior to continued treatment or tapered treatment, leading to more disease flares.
Abs#0545 @RheumNow #ACR22 https://t.co/CBRnVdxXVo
Robert B Chao, MD doctorRBC ( View Tweet)
2022 ASAS-EULAR recommendation lit review in Abs 0413 at #ACR22 shows new evidence on education & exercise and confirms efficacy in axSpA. Tofa, UPA, FIL have shown efficacy in r-axSpA. @RheumNow https://t.co/8E9RZQ8Gz4 https://t.co/5QPO5eddFH
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting findings from Abs 0417 - when early axSpA is defined by duration of symptoms, only nr-axSpA tx w/ bDMARDs may lead to better outcomes vs early or established axSpA. #ACR22 @RheumNow https://t.co/8aGdyJRvv1 https://t.co/chAEGPicPd
Dr. Rachel Tate uptoTate ( View Tweet)
NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy.
*Numerical reduction in syndesmophytes 11% vs. 25%
Abs#0546
@RheumNow #ACR22
#ACRBest https://t.co/pG5F3xdsh9
Robert B Chao, MD doctorRBC ( View Tweet)
Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip
Dr. Rachel Tate uptoTate ( View Tweet)
In GCA, do you give pulse IV methylpred to patients with visual symptoms (instead of ongoing oral pred)? #ACR22 @RheumNow
David Liew drdavidliew ( View Tweet)
#Abstr 0545 GO-BACK Trial
Continue vs Withdrawal of GOL in nr-axSpA with inactive disease
- Full tx withdrawal associated w/ dx flare
- Re-treatment -->rapid clinical response after flare
- qMonthly tx --> higher rates of disease activity improvement
@RheumNow #ACR22 https://t.co/Z3bhA9D4RQ
Akhil Sood MD AkhilSoodMD ( View Tweet)
P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares
📌Adjusted:⬇️c3, plasma alb & proteinuria levels at BL
📌Non-adj: antidsDNA+, antiSm+ addt'l predictors
🧐p alb & antiSm+ potential predictors?
#ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe
sheila RHEUMarampa ( View Tweet)
Majority of pts withdrawn from IXE to PBO recaptured at least LDA & over half met ID w/ IXE retreatment. This may help us clinically with pts who have treatment interruptions. Abs 0427 #ACR22 @RheumNow https://t.co/m4c3P8l25m https://t.co/iQshG1oq2Y
Dr. Rachel Tate uptoTate ( View Tweet)
The CONSUL trial by Dr Proft et al. compared impact of CEL+GOL vs. GOL alone on radiographic spinal progression in AS showed no significant difference bet. the 2 grps in mSASSS change after 108 wks.
Risk stratify pts who will benefit from tx
#ACR22 @RheumNow ABST#0546 #ACRBest https://t.co/jWwX7w85ur
sheila RHEUMarampa ( View Tweet)
Clinical pearl! First-line tx w/ bio-originator or biosimilar ADA/ETA showed similar effectiveness & safety in long-term cohort of axSpA pts. Response to treatment was also similar between groups. Abs 0431 #ACR22 @RheumNow https://t.co/bGGXk51hIG https://t.co/PSsX3MpSXt
Dr. Rachel Tate uptoTate ( View Tweet)
Presenting our last (virtual) #JAKpot poster at #ACR22 1-3 pm ET (7-10 CET) in the RA treatment session.
Does anyone know what we will are supposed to do? Stay in front of our computer for 2 hours? @rheum_cat @ProftDr @DrMiniDey @EMEUNET @KragstrupTW https://t.co/uCNMezmJ4V
Kim Lauper ☮️🕊️ k_lauper ( View Tweet)
#ACR22 KNOWLEDGE bowl Dr. Namrata Singh, a judge this year, lead the U Iowa team in their bowl championship 3-peet, 2014, ‘15 & ‘16.
😷Dr. Rebecca Tuetken BeckySueToo ( View Tweet)
Attending Difficult to treat RA…looking forward to learning new things about this. #Gowithus #ACR22 @IFAiArthritis https://t.co/ChET0ckm0X
Deb Constien debconstien ( View Tweet)
@erasmusmcintl @RheumNow Data here from @earlyarthritis (CATCH Canada cohort), similar results.
It's not just pain differences - but that's real too. It's lots of things, but whatever the case we ignore sex and gender's impact in RA at our peril.
ABST0532 #ACR22 @Janetbirdope @TheLancetRheum @RheumNow https://t.co/27uQmNAlPF
David Liew drdavidliew ( View Tweet)
How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines:
💉Pre-vax:
💊csDMARDs - hold time 4 wks
💊bDMARDs -hold time of one dosing interval
💉Post-vax: hold DMARDs for 4 wks
#ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC
sheila RHEUMarampa ( View Tweet)
#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf
Dr. Rachel Tate uptoTate ( View Tweet)
Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal https://t.co/WdkmkCWClO #ACR22 @RheumNow https://t.co/qlNUFhnuJQ
Dr. Antoni Chan synovialjoints ( View Tweet)